Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant in Metastatic Breast Cancer After Aromatase Inhibitor Failure
NCT00012025Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2001
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant in breast cancer, sponsored by Cancer and Leukemia Group B. Primary endpoint: Objective Response Rate at 10 years. Started May 2001; status: completed.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00012025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012025.